SAFE ORTHOPAEDICS (Paris:SAFOR) (FR0012452746 – SAFOR), a company offering innovative ranges of sterile implants combined with their single-use instruments, is announcing today that the first surgeries using its new SteriSpineCC range for cervical vertebrae surgeries have gone ahead successfully.
Designed, like all Safe Orthopaedics’ products, for single use, the SteriSpineCC kit offers the same benefits – ease of use with its sterile instrumentation pre-mounted on the implant that shortens operating times and reduces the cost of the procedure, while improving patient safety and ensuring availability at all times.
Extending the existing product range for lumbar and trauma surgery, this new addition applies Safe Orthopaedics’ advanced technology in the field of single-use instruments for back surgery to cervical surgeries.
Pierre Dumouchel, Interim Chief Executive Officer of Safe Orthopaedics, commented: “The launch of SteriSpineTMCC represents another milestone in our expansion and in the execution of Safe Orthopaedics’ mission. We want to provide a solution facilitating the treatment of degenerative cervical conditions by delivering the combined benefits of a stable anatomical implant with our single-use instruments. This type of cervical surgery needs to be reliable, effective and rapid so that it can guarantee the best possible clinical outcome. This type of surgery opens the door to fast-track and outpatient surgery.”
To date, four surgeries have been carried out by Prof. Jean-Charles Le Huec, a surgeon with a worldwide reputation and the head of the orthopaedics-spine trauma unit at Bordeaux University Hospital, and by Dr. Antonio Faundez, a surgeon at Hôpital de la Tour in Switzerland, a center of excellence for spine surgery.
“This new system is genuinely straightforward and makes the surgery safer by helping to reduce operating times”, commented Prof. Jean-Charles Le Huec. “In this product I can see and appreciate the benefits of Safe Orthopaedics’ philosophy, which began with the SteriSpine PS and LC lumbar systems”, he added.
“Always ready for use, the SteriSpineCC range is genuinely easy to use at every stage of the surgical process”, concluded Dr. Antonio Faundez.
The SteriSpineCC kit is scheduled for launch in the third quarter of 2016 in all the territories covered by Safe Orthopaedics. The Company will thus be moving into a new market segment worth an estimated $500m1.
Next publication: 2016 Q2 revenue, July 12, 2016 (after the market closes)
About Safe Orthopaedics:
Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the SteriSpine™ Kits are CE-marked and FDA cleared. The company is based at Eragny-sur-Oise (France), and has 37 employees.
For more information, visit: www.SafeOrtho.com
1 Millenium data.
Contacts
Safe Orthopaedics
Thierry Lambert, Tel.: +33 (0)1 34 21 50 00
CFO
investors@safeorthopaedics.com
or
NewCap
Julien Perez / Valentine Brouchot
Investor Relations
or
Nicolas Merigeau
Media Relations
Tel.: +33 (0)1 44 71 94 94
SafeOrtho@newcap.eu